In postmenopausal women with early breast cancer, the third-generation aromatase inhibitors (AIs; anastrozole, exemestane, and letrozole) have already been shown to be of worth in multiple huge well-conducted clinical studies as preliminary adjuvant endocrine therapy, after many years of tamoxifen, so that as expanded adjuvant endocrine therapy after about 5 many years of tamoxifen [1-8].… Continue reading In postmenopausal women with early breast cancer, the third-generation aromatase inhibitors